Evidence map›Paper›PMID 23200667›Full record

ArticleCancer letters2013

GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft.

Junsheng Fu, Mariana Rodova, Sanjit K Roy, Jay Sharma, Karan P Singh, Rakesh K Srivastava, Sharmila Shankar

Erratum issuedAbstract read
In one paragraph

Article in Cancer letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 93 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 1 synthesis or guideline pooled it, 148 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Pancreatic cancer stemness: dynamic status in malignant progression.Journal of experimental & clinical cancer research : CR · 2023
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Cathepsin KFrontiers in cell and developmental biology · 2022
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Junsheng FuDepartment of Pathology and Laboratory Medicine, The University of Kansas Cancer Center, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA.
Mariana Rodova
Sanjit K Roy
Jay Sharma
Karan P Singh
Rakesh K Srivastava
Sharmila Shankar
The University of Kansas Cancer Center · USReprogenetics · USUniversity of Alabama at Birmingham · USUniversity of Kansas Medical Center · US

Funding

Chemoprevention of Pancreatic Cancer by EGCGR01CA125262 · NCI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI DHAR, ANIMESH · 2008 to 2012
$1.7M
Mechanisms of Chemoprevention by ResveratrolR01CA114469 · NCI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI SRIVASTAVA, RAKESH K. · 2005 to 2009
$726k
NCI NIH HHS R01 CA114469NCI NIH HHS R01CA114469NCI NIH HHS R01 CA125262NCI NIH HHS R01CA125262NCI NIH HHS R01CA125262-02S1
6 · The paper itself

Abstract

Multiple lines of evidence suggest that the Sonic Hedgehog (Shh) signaling pathway is aberrantly reactivated in pancreatic cancer stem cells (CSCs). The objectives of this study were to examine the molecular mechanisms by which GANT-61 (Gli transcription factor inhibitor) regulates stem cell characteristics and tumor growth. Effects of GANT-61 on CSC's viability, spheroid formation, apoptosis, DNA-binding and transcriptional activities, and epithelial-mesenchymal transition (EMT) were measured. Humanized NOD/SCID/IL2R gamma(null) mice were used to examine the effects of GANT-61 on CSC's tumor growth. GANT-61 inhibited cell viability, spheroid formation, and Gli-DNA binding and transcriptional activities, and induced apoptosis by activation of caspase-3 and cleavage of Poly-ADP ribose Polymerase (PARP). GANT-61 increased the expression of TRAIL-R1/DR4, TRAIL-R2/DR5 and Fas, and decreased expression of PDGFRα and Bcl-2. GANT-61 also suppressed EMT by up-regulating E-cadherin and inhibiting N-cadherin and transcription factors Snail, Slug and Zeb1. In addition, GANT-61 inhibited pluripotency maintaining factors Nanog, Oct4, Sox-2 and cMyc. Suppression of both Gli1 plus Gli2 by shRNA mimicked the changes in cell viability, spheroid formation, apoptosis and gene expression observed in GANT-61-treated pancreatic CSCs. Furthermore, GANT-61 inhibited CSC tumor growth which was associated with up-regulation of DR4 and DR5 expression, and suppression of Gli1, Gli2, Bcl-2, CCND2 and Zeb1 expression in tumor tissues derived from NOD/SCID IL2Rγ null mice. Our data highlight the importance of Shh pathway for self-renewal and metastasis of pancreatic CSCs, and also suggest Gli as a therapeutic target for pancreatic cancer in eliminating CSCs.

Indexed as

AnimalsApoptosisCell Growth ProcessesCell Line, TumorDown-RegulationGene Expression Regulation, NeoplasticHedgehog ProteinsHEK293 CellsHumansKruppel-Like Transcription FactorsMiceMice, Inbred NODMice, SCIDNeoplastic Stem CellsNuclear ProteinsPancreatic NeoplasmsGANT 61GLI1 protein, humanGLI2 protein, humanHedgehog ProteinsKruppel-Like Transcription FactorsNuclear ProteinsPyridinesPyrimidinesRNA, Small InterferingSHH protein, humanTranscription FactorsZinc Finger Protein GLI1Zinc Finger Protein Gli2

Identifiers

PMID23200667
PMCPMC4153855
OpenAlexW2050406835

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.